Zusammenschluss soll voraussichtlich am bzw. um den 15. Juni 2022 abgeschlossen werden Stammaktien von Alvotech sollen ab 16. Juni 2022 am Nasdaq Stock Market in New York und ab 23. Juni 2022 am...
Le regroupement d'entreprises devrait être finalisé (vers) le 15 juin 2022 Les actions ordinaires d'Alvotech devraient être négociées sous le nouveau mnémo "ALVO" à compter du 16 juin 2022 au...
Business Combination anticipated to close on or about June 15, 2022 Ordinary shares of Alvotech expected to trade under the new ticker symbol “ALVO” from June 16, 2022 on The Nasdaq Stock Market...
Business Combination remains subject to satisfaction of customary closing conditions, including shareholder approval Oaktree Acquisition Corp. II (NYSE: OACB) (“OACB” or the “Company”) announced...
The confirmatory clinical, safety and efficacy study for AVT04, biosimilar candidate to Stelara® (ustekinumab) met its primary endpoint AVT04 (ustekinumab) is part of a broader pipeline of...
- Results from pharmacokinetic (PK) similarity study demonstrate bioequivalence of AVT04 (ustekinumab) to the reference product Stelara® Alvotech Holdings S.A. (“Alvotech”), a global biotech...
Alvotech Holdings S.A. (“Alvotech S.A.”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree...
Alvotech et Oaktree Acquisition Corp. II ont mis en place des facilités de financement afin de renforcer la position des fonds propres de la société et de remplacer tout capital racheté dans le...
Alvotech und Oaktree Acquisition Corp. II richten Finanzierungsfazilitäten ein, um die Kapitalposition des Unternehmens zu stärken und Mittel für die im Rahmen ihrer geplanten Fusion ausgeübten...
Alvotech e Oaktree Acquisition Corp. II hanno creato strumenti finanziari volti a migliorare la posizione finanziaria della società e a reintegrare eventuale capitale riscattato nel quadro della...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.